Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
EPIsoDE
DRKS00024484Phase 2Completed
- Sponsor
- Central Institute of Mental Health
- Start
- Feb 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of psilocybin in major depressive disorder (MDD) (4 arms), sponsored by Central Institute of Mental Health. Started Feb 2021; status: completed.
02
Drugs
psilocybin
03
Conditions
major depressive disorder (MDD)
Beyond the preview
Go deeper on DRKS00024484.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on DRKS00024484.